2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2828

Profiling Immunogenic Bacteria within the Microbiota of ZAP-70 Mutant SKG Mice Associated with Spondyloarthritis and Ileitis Using IgA-SEQ
Abstract Number: 857

Prognosis Value of Geriatric Assessment Scales in Older Adults with New Onset ANCA-Associated Vasculitis: A Pilot Retrospective Study
Abstract Number: 3138

Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis
Abstract Number: 495

Prognostic Significance of Residual Inflammation and Autoantibodies for Disease Relapse upon DMARD Suspension in Patients with Rheumatoid Arthritis in Sustained Remission after DAS-Driven Therapy
Abstract Number: 1796

Progression of Atherosclerosis Might be Prevented By Decrease of Serum Resistin Level after Glucocorticoid Therapy in Patients with Systemic Autoimmune Disease
Abstract Number: 3084

Progression of Lupus Pathology Is Correlative with Cardiac Magnetic Resonance Imaging Abnormalities, Diminished Function, and Inflammatory Histopathology in an Animal Model
Abstract Number: 1798

Progression of Noncalcified and Calcified Coronary Plaque (by CT Angiography) in SLE
Abstract Number: 709

Progression of Patients with Non-Radiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population-Based Cohort Study
Abstract Number: 439

Progression of Radiographic Joint Destruction in Patients with Rheumatoid Arthritis Treated with a Biologic Agent in Combination with Methotrexate Versus a Biologic Alone: A Systematic Review and Meta-Analysis of Randomized Trials
Abstract Number: 273

Progression Predictive Factors in Patients with Undifferentiated Connective Tissue Disease: A Cohort Study
Abstract Number: 1630

Progressive Destruction of Large Joints in Patients with Rheumatoid Arthritis Treated with Biologic Agents
Abstract Number: 1448

Progressive Pseudorheumatoid Arthropathy of Childhood (PPAC) – a Single Center Case Series
Abstract Number: 804

Prolactin Induces Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation in Primary Monocytes Comparable to Changes Seen in Monocytes from Systemic Lupus Erythematosus Patients
Abstract Number: 759

Prolactin Level Is Independently Associated with Circulating CD4+CD28null in Systemic Lupus Erythematosus Patients
Abstract Number: 1410

Prolotherapy Versus Corticosteroid Injections and Phonophoresis for the Treatment of Plantar Fasciitis: A Randomized Controlled Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].